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One Sentence Summary: Cyclin-dependent-like kinase 5 (Cdkl5) controls nociception in human 











Cyclin-dependent-like kinase 5 (Cdkl5) gene mutations lead to an X-linked disorder that is 
characterized by infantile epileptic encephalopathy, developmental delay and hypotonia. However, we 
found that a substantial percentage of these patients also report a previously unrecognised anamnestic 
deficiency in pain perception. Consistent with a role in nociception, we discovered that Cdkl5 is 
expressed selectively in nociceptive dorsal root ganglia (DRG) neurons in mice and in iPS-derived 
human nociceptors. CDKL5 deficient mice display defective epidermal innervation and conditional 
deletion of Cdkl5 in DRG sensory neurons impairs nociception, phenocopying CDKL5 deficiency 
disorder in patients. Mechanistically, Cdkl5 interacts with CaMKIIα to control outgrowth as well as 
TRPV1-dependent signaling, which are disrupted in both Cdkl5 mutant murine DRG and human iPS-
derived nociceptors. Together, these findings unveil a previously unrecognized role for Cdkl5 in 
nociception, proposing an original regulatory mechanism for pain perception with implications for 
future therapeutics in CDKL5 deficiency disorder. 
 
Introduction 
Mutations in the X-linked Cdkl5 gene, encoding the cyclin-dependent-like kinase 5, are associated with 
the CDKL5 Deficiency Disorder (CDD) that is characterized by early-onset intractable seizures, severe 
intellectual disability, and motor impairment(1, 2). Cdkl5 is strongly expressed in the central nervous 
system (CNS), particularly in neurons of the cortex and of the hippocampus (3). Defective Cdkl5 
impairs proper brain development, learning and memory, neuronal activity, including molecular 
processes related to neuronal depolarization and synapse formation (4-7). Cdkl5 is activated by 
neuronal activity and it has also been implicated both in the phosphorylation and interaction with 
nuclear as well as cytoplasmic proteins potentially modulating gene expression and cytoskeleton 
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changes ultimately affecting neuronal activity and cell survival (2, 5, 8, 9). Recently microtubule and 
centrosome-associated proteins have been identified as targets of Cdkl5 kinase activity, including 
MAP1S, EB2, ARHGEF2, CEP131 and DLG5, whose regulation is likely to affect axonal transport, 
outgrowth and synaptic plasticity (10, 11).  
CDD remains a disease without a cure, whose fundamental molecular and cellular mechanisms are still 
in need of much investigation and whose full clinical spectrum remains only partially characterized. 
An important current limitation is that unlike patients, CDD mutant mice do not develop epilepsy (4, 
12-14). This makes the identification of Cdkl5-dependent mechanisms or potential treatments with an 
impact on the human phenotype very challenging. Here, we discovered that CDD patients and animal 
models display an impairment in nociception and that Cdkl5 is required for peripheral nociceptive 
signaling in dorsal root ganglia (DRG) neurons in mice and in induced pluripotent cell (iPS)-derived 
human nociceptors. Mechanistically, conditional deletion of Cdkl5 in DRG sensory neurons impairs 
nociception, phenocopying CDKL5 deficiency disorder in patients. Lastly, we discovered that Cdkl5 
interacts with CaMKIIα to control outgrowth of sensory neurons as well as TRPV1-dependent 
signaling including in iPS-derived neurons from CDD patients. Together, these findings reveal a 
previously unrecognized role for Cdkl5 in nociception and they suggest an original peripheral 
regulatory mechanism for pain processing with implications for future therapeutic interventions in 
CDD. 
Results 
Alteration in pain perception in CDD patients 
In a recent effort to broadly characterise the clinical phenotype, variation and natural history of CDD, 
the International CDKL5 Database (ICDD) (https://www.cdkl5.com/cdkl5-international-registry-
database/) was established in 2012. Included in the database are responses to questions given to 
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caregivers about whether their child experiences alterations in pain perception. Analysis of this clinical 
data source allowed the identification of a previously unrecognized occurrence of alterations in pain 
perception. 
Patients in the ICDD were classified by age group, gender and mutation type (Table 1). 
Classification of individual CDKL5 mutations was based on predicted structural and functional 
phenotypic consequences similar to the groupings used in a previous study (15). In our analysis we 
have grouped together mutations leading to lack of functional protein and missense/in-frame 
mutations within catalytic domain and TEYmotif and compared them with mutations affecting the 
regulatory domains of Cdkl5 i.e. truncations after aa172.  
Multinomial logistic regression was used to estimate the risk of altered pain sensitivity relative to 
no change in pain sensitivity (i.e. reduced pain sensitivity vs. normal pain sensitivity) in the overall 
sample, as well as in each category of age group, gender and mutation type (i.e. within category 
comparison) (Table 1). We then used the same model to evaluate the relative risk ratios of altered 
pain sensitivity in each category compared to the reference category (age group: 0-2 years, gender: 
female; mutation type: truncations after aa172) (i.e. between category comparison) (Table 1). Point 
estimates and their 95% confidence interval were reported. 
We found that altered pain sensitivity in their children was reported by 53.0% (122/230) of caregivers. 
Amongst these a total of 57.4% (70/122) specifically reported decreased pain sensitivity, 19.7% 
(24/122) specifically reported enhanced sensitivity and 22.9% (28/122) reported both. 202 caregivers 
provided specific responses including either reduced (70/202, 34.7%) or enhanced pain perception 
(24/202, 11.9%) (Table 1). Amongst those who reported either reduced or enhanced pain sensitivity, 
a total of 74.4% (70/94) reported decreased and 25.5% (24/94) increased pain perception. The 
likelihood of the response being specifically reduced pain perception was measured as risk ratio (RR) 
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of reduced or enhanced pain sensitivity versus normal pain perception, whilst the relative risk ratio 
(RRR) was used to represent the relative change in the risk ratio in each category compared to the 
reference. As shown in Table 1 reduced pain perception was more likely to be reported than enhanced 
pain perception (RR 2.92, 95% CI 2.89,7.00; p<0.001). Compared with those aged two years or under, 
individuals aged six years and over were reported to have an increased likelihood of reduced sensitivity 
to pain (RRR 2.74, 95% CI 1.36,5.53; p=0.005). Moreover, compared with those with mutations in the 
Cdkl5 regulatory domain (truncations after aa172), those with a non-functional protein (including 
missense/in-frame mutations within catalytic domain and TEY motif) were also reported to have an 
increased likelihood of reduced sensitivity to pain (RRR 1.63, 95% CI 0.87,3.06; p=0.124). However, 
we did not identify any differences by gender (RRR 1.03, 95% CI 0.44,2.45; p=0.941). Reduced was 
significantly more likely than enhanced pain perception at each age group (0-2 years old, (RR 3.00, 
95% CI 1.28,7.06; p=0.012); 3-5 years old, (RR 2.67, 95% CI 1.04,6.81; p=0.040); 6+ years old, (RR 
3.00, 95% CI 1.52,5.94; p=0.002) and for each gene mutation group studied (no functional protein, 
(RR 2.94, 95% CI 1.67,5.18; p<0.001); truncation after aa172, (RR 2.88, 95% CI 1.29,6.42; p=0.010), 
and for females (RR 3.16, 95% CI 1.89,5.29; p<0.001).  
 
Cdkl5 localizes to human and murine sensory neurons and is required for nociception 
Since primary nociceptors are localized in the dorsal root ganglia, we initially investigated whether 
Cdkl5, so far localized to the CNS, was also expressed in the peripheral nervous system in murine as 
well as human nociceptors. Surprisingly, immuno and co-immunohistochemistry studies in DRG 
revealed that Cdkl5 is indeed expressed and mainly found in the cytoplasm of small diameter DRG 
neurons (Fig. 1A-C), where the signal becomes detectable after the age of post-natal day P45 (fig. 
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S1A,B). Around 90% of Cdkl5 positive neurons express the nociceptive markers CGRP or IB4, while 
only a small percentage express PARV or NF200 (Fig. 1D-F).  
The expression of Cdkl5 in murine DRG was confirmed by RT-PCR and immunoblotting (fig. S1C,D), 
where Cdkl5 was expressed although to a lower degree compared to the brain. Additionally, Cdkl5 
mRNA neuronal expression was detected by RT-PCR from sorted GFP+ DRG neurons (fig. S1E,) in 
line with previous single cell studies (16) (17). 
 
Next, in order to find whether Cdkl5 was also expressed in human nociceptors, we differentiated iPSC 
obtained from human skin biopsies into nociceptors. After having confirmed the differentiation of iPSC 
by immunolabelling for βIII-Tubulin as neuronal and CGRP as nociceptor marker respectively (fig. 
S2A-E), we observed that Cdkl5 was indeed expressed in human nociceptors (Fig. 1G,H). 
In order to directly address whether the expression of Cdkl5 in DRG sensory neurons was required for 
nociception, we took advantage of the conditional deletion of Cdkl5 in sciatic DRG neurons by 
injecting an AAV5-creGFP or control GFP virus to the sciatic nerve of Cdkl5-floxed mice (12) (Fig. 
2A, fig. S3A, B). Since the cre-virus reduces Cdkl5 expression selectively in DRG neurons, the strong 
reduction of Cdkl5 signal by immunoblotting strongly supports the selective neuronal expression in 
DRG ganglia as well as the efficiency of the deletion (Fig. 2B, C). Cdkl5 conditionally deleted mice 
showed an increase in paw withdrawal latency and threshold in response to noxious hot temperature 
(Haargraves plantar test) and noxious mechanical stimulation (Von Frey) respectively (Fig. 2D,F). 
We performed the same functional tests in Cdkl5 mutant mice, an established mouse model of CDD 
carrying a nonsense mutation (stop codon) leading to deletion of Cdkl5-Ex6 (4). Here, we found a 
reduction in nociception compared to WT littermates that phenocopied what observed in Cdkl5 
conditionally deleted mice (Fig. 2E,G).  
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Importantly, in Cdkl5 conditionally deleted mice additional sensory modalities were unaffected as 
indicated by the time-to-contact and the time-to-removal during the adhesive removal test (18) (Fig. 
2H), and by the thermal place preference test, evaluating the non-nociceptive thermal sensitivity (fig. 
S3C). Sensorimotor functions as assessed by the gridwalk task (19) were also unaltered (Fig. 2I), 
suggesting a selective role for CDKL5 in nociception. Importantly, the number of nociceptors did not 
differ between WT and Cdkl5 null mice (fig. S4). 
Together, these data suggest that Cdkl5 is required for physiological nociception that relies upon the 
expression of Cdkl5 in DRG neurons.  
Cdkl5 controls the outgrowth of human and murine sensory neurons via a CaMKII-dependent 
mechanism  
To investigate the signaling pathways involved in Cdkl5-dependent pain transmission, we decided to 
identify interactors of Cdkl5 in vivo. To this end, we performed immunoprecipitation of Cdkl5 from 
the murine cortex, where the kinase is highly enriched, followed by mass spectrometry of the eluate 
(Suppl. File 1 and fig. S5A). Considering the normalized protein ratios of each immunoprecipitation 
experiment (n=6), we identified 23 proteins co-immunoprecipitating with Cdkl5 (fig. S5B). 
Interestingly, 74% of them correspond to genes associated with neuronal activity, neural development 
and epilepsy (fig. S5C-F), supporting the physiological relevance of our pool of interactors. Top ranked 
Cdkl5 co-immunoprecipitating proteins included CaMKIIα, putatively the strongest interactor of 
Cdkl5, and some proteins associated with the neuronal cytoskeleton, such as Myh10 (20), Tubb3 (21) 
and Dynch1h1 (22-25) (fig. S5G). The association with CaMKIIα suggests also a role for Cdkl5 in 
calcium-dependent signaling, neuronal activity (26) and in cytoskeleton remodeling (27-32).   
Previous immunohistochemical studies have found that CaMKII is expressed in DRG nociceptors (33), 
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where it plays a role in the regulation of neurite outgrowth (34). In particular, CaMKII is expressed in 
TRPV1-immunoreactive nociceptors, in both CGRP+ and IB4+ subpopulations, where it is required 
for capsaicin-mediated nociception via modulation of TRPV1; capsaicin stimulation of TRPV1 and 
calcium entry activate CaMKII that is in turn required to potentiate TRPV1 signaling (35, 36). Hence, 
we hypothesised that Cdkl5 could be a partner of CaMKIIα in the regulation of pain both via 
modulation of cytoskeleton remodelling and nociception signaling pathways.  
First, we examined by confocal microscopy the co-expression of Cdkl5, CaMKIIα and TRPV1 in DRG 
neurons and we found that they co-localize in most DRG neurons (Fig. 3A-C, fig. S6). Next, we 
confirmed, by co-immunoprecipitation and immunoblotting from brain extracts, that Cdkl5 does 
interact with CaMKIIα in vivo (fig. S5H). Similarly, co-immunoprecipitation experiments after 
overexpression of CDKL5 in HEK293 cells, or of its inactive kinase dead form CDKL5-K42R and 
CaMKIIα, confirmed the interaction between the active form of CDKL5 and CaMKIIα. Importantly, 
no interaction was observed between CaMKIIα and CDKL5-K42R (fig. S5I), which showed lack of 
kinase activity in an in vitro kinase assay (fig. S5J), supporting the specificity of the findings. We 
finally established the molecular proximity between Cdkl5 and CaMKIIα in DRG neurons by using 
the Proximity Ligation Assay (Fig. 3D,E), supporting the co-expression and co-immunoprecipitation 
data.  
 We next investigated whether Cdkl5-CaMKIIα signaling axis would be required for the 
outgrowth of DRG neuronal processes. Assessment of neurite outgrowth was carried out in both murine 
and human iPSC derived nociceptors from Cdkl5 null mice and CDKL5 deficiency disorder patients. 
We found that cultured DRG neurons from Cdkl5 mutant mice display impaired neurite outgrowth in 
CGRP positive neurons (Fig. 4A,C), and this is rescued to the WT amounts by viral-mediated 
overexpression of CDKL5 (Fig. 4E; fig. S7). On the contrary, outgrowth in proprioceptive 
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parvalbumin positive neurons remained unaffected by Cdkl5 loss of function (Fig. 4B,D), indicating a 
specific role for Cdkl5 in nociceptors. Importantly, impaired neurite outgrowth was also observed in 
iPSC-derived nociceptive DRG neurons (CGRP+) obtained from skin biopsies of CDKL5 patients, 
compared with the respective isogenic controls (Fig. 4F,G). CGRP+ neurons represent 30-40% of WT 
and mutant DRG neurons and more than 90% of iPSC derived sensory neurons were βIII-Tubulin+ 
(fig. S2D). Capsaicin responding cells were ~60% of the KCl responding murine DRG cultured 
neurons, while they were more than 90% of the KCl responding iPSC derived neurons, both in mutant 
and isogenic cultures, indicating functionality of the nociceptors (fig. S2E). Interestingly, we found 
that neurite outgrowth was impaired in neurons derived from patients carrying a Cdkl5 mutation 
compromising the kinase active site and the TEY motif, but not in neurons where only the terminal 
part of the Cdkl5 tail is lost (Fig. 4H; Table 1).  
Next, we asked whether CaMKII activity was required for Cdkl5-dependent neurite outgrowth. Indeed, 
we found that DRG outgrowth was significantly impaired following administration of the specific 
CaMKII enzymatic inhibitor KN93, while its inert structural analog KN92 did not have an effect (Fig. 
5A,B). Interestingly, KN93 did not further reduce outgrowth in Cdkl5 mutant cells (Fig. 5A,B), 
indicating that CDKL5 and CaMKII belong to the same signaling pathway. Importantly, CDKL5 
overexpression rescued outgrowth defects in Cdkl5 mutant knockout DRG neurons, but this effect was 
blocked by KN93. These data together suggest that Cdkl5-dependent DRG outgrowth relies on 
CaMKII. 
Since epidermal innervation is needed for proper nociception and it is a dynamic process requiring 
continuous cytoskeleton remodeling and outgrowth, we examined if Cdkl5 deficiency was associated 
with a defect in epidermal innervation.  
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Indeed, immunohistochemical analysis of skin innervation revealed impairment in epidermal but not 
dermal innervation in Cdkl5 mutant versus WT adult mice (Fig. 6A-E). We also measured epidermal 
innervation from the post-natal day 4 (P4) to adulthood (P70) and found that Cdkl5 mutant mice display 
deficient epidermal innervation only in adulthood (P70), and not at earlier stages (P4 or P16; Fig. 6B). 
In support of these data, we found, by immunoblotting of skin lysates, that the specific neuronal and 
axonal proteins PGP9.5, CGRP and βIII-tubulin are reduced in Cdkl5 mutants as compared to WT adult 
mice (Fig. 6F,G). However, consistent with the selective reduction of nociceptive fibres in the 
epidermis of Cdkl5 mutant mice, the expression of these axonal proteins is not reduced in sciatic nerve 
lysates (Fig. 6H,I) or after immunostaining for CGRP (Fig. 6J,K), in Cdkl5 mutant mice.  
Cdkl5 is required for TRPV1/CaMKII-dependent signaling and nociception in sensory neurons and in 
vivo 
Since TRPV1 activity relies on CaMKII-dependent interaction and phosphorylation (35, 36), we 
hypothesized that TRPV1 signaling might require Cdkl5. Therefore we aimed to address whether 
Cdkl5 and CaMKII regulate TRPV1-dependent calcium signaling after stimulation with the well-
established ligand capsaicin, which activates nociception by engaging with its receptor TRPV1 (37-
39).  We used capsaicin as specific activator of TRPV1 and we measured calcium influx in iPS derived 
nociceptors to find that capsaicin-induced increase in calcium is impaired in neurons carrying CDKL5-
mutations involving the kinase active domain (E55fsX74) and the TEY motif (G155fsX197) (Fig. 5C). 
Similarly, capsaicin-induced calcium responses were impaired in Cdkl5 mutant murine DRG explants 
and cultured neurons, where we established that overexpression of AAV9-CDKL5 rescued the defect 
in calcium response (Fig. 5D,E,H). When we blocked CaMKII signaling in cultured WT DRG neurons 
by using KN93, in contrast to its inert structural analog KN92, we observed, as expected, that KN93 
inhibited the activation of TRPV1 after administration of capsaicin. Inhibition was similar to what 
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observed in Cdkl5 mutant cells, where the CaMKII inhibitor did not further decrease calcium amount 
(Fig. 5E). Delivery of KN93 after overexpression of CDKL5 in Cdkl5 mutant DRG neurons blocked 
the rescue in calcium mobilization after capsaicin delivery (Fig. 5F). Together, these data confirm our 
initial hypothesis that CaMKII is required for Cdkl5-dependent calcium responses after capsaicin.  
To further test the role of CaMKII signaling in Cdkl5 function, we infected cultured WT and Cdkl5 
mutant DRG neurons with AAV particles expressing the CaMKII-AIP (Autocamtide-2-related-
Inhibitor Peptide) plasmid (40), or an active CDKL5 plasmid to rescue Cdkl5 function in null neurons. 
We then measured neurite outgrowth and calcium following capsaicin stimulation (fig. S8).  
CaMKII-AIP infected neurons showed impaired neurite outgrowth (fig. S8A,B) and reduced capsaicin-
dependent calcium mobilization (fig. S8C,D) to a similar degree as Cdkl5 mutant knockout DRG 
neurons. Both outgrowth and calcium were not further impaired in Cdkl5 mutant knockout DRG 
neurons after CaMKII-AIP infection, suggesting functional interaction of the two proteins. Lastly and 
importantly, neurite outgrowth and capsaicin-dependent calcium induction were rescued by 
overexpression of Cdkl5 (fig. S8A-D); however, this failed when CaMKII was inhibited (fig. S8A-D), 
indicating that CaMKII is required to mediate Cdkl5 activity. 
 Finally, we hypothesized that capsaicin signaling would also be compromised in vivo leading 
to biochemical and behavioral impairments in Cdkl5 deficient mice. In line with this hypothesis, we 
found that both the licking behavior and cell signaling response to intradermal injection of capsaicin 
were impaired in vivo in Cdkl5-/y mutant mice and following conditional deletion of Cdkl5 specifically 
in sciatic DRG sensory neurons. In fact, the time spent licking the right paw after injection of capsaicin 
(1μg) was significantly reduced both in Cdkl5-/y mice and in AAV5-CRE vs AAV5-GFP treated Cdkl5-
floxed mice (vehicle was injected in the left paw) (Fig. 7A-C). Consistently, five minutes after 
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capsaicin injection in the right paw, pCaMKIIα was upregulated in DRG on the injected side. in WT 
but not in Cdkl5-/y mice, supporting a defective signaling response (Fig. 7D-F). We confirmed defective 
transmission of the stimulus in Cdkl5-/y mice also to the right dorsal horn of the spinal cord by 
measuring pERK1/2 expression, typically activated by capsaicin-TRPV1 signaling in lamina I-II of the 
dorsal horn (41). Indeed, pERK1/2 was induced only in WT but not in Cdkl5-/y mice following 
intradermal injection of capsaicin  (Fig. 7G-I) (42, 43).  
Discussion 
Our data reveal a previously unknown function of Cdkl5 in the regulation of primary nociception in 
the peripheral nervous system as shown by impaired nociception following conditional deletion of 
Cdkl5 in DRG sensory neurons. Specifically, we found that Cdkl5 is required for CaMKII-dependent 
TRPV1 signaling and outgrowth of sensory neurons in both CDD murine and human neurons. In vivo, 
in a CDD animal model, this translates into impaired capsaicin-dependent nociceptive signaling and 
behavioral responses as well as in reduced epidermal innervation. 
The anatomical, mechanistic and functional data all together support the initial anamnestic evidence 
that over 34% of CDKL5 patients have defective pain perception. The clinical questionnaire we 
employed should not be considered as an exhaustive clinical piece of data per se but rather a clinical 
indication that generated a hypothesis guiding further experiments in animal models and human iPSC.  
In a much smaller percentage of patients with enhanced pain perception, cortical hyperexcitability, 
which is a typical feature of these patients, might lead to dysfunctional central processing of 
nociception. This might be in line with disorders affecting cognition and neuronal activity in the central 
nervous system such as ASD and Rett syndrome (RTT), where it has been proposed that altered pain 
sensitivity is related to a dysfunctional mode of cortical pain processing, rather than to defective 
primary peripheral nociception (44) (45-48). Therefore, it is possible that modest impairment in 
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peripheral pain perception and marked cortical hyperexcitability might coexist in a subset of patients 
leading to the net effect of enhanced pain perception. Alternatively and similarly to the protein 
SHANK3 that regulates TRPV1 and heat pain as a loss-of-function(49) and touch sensation as a gain-
of-function in ASD(50), we cannot rule out that Cdkl5 might have a dual loss and gain-of-function role 
in specific sensory neuron subtypes. 
CDD and RTT are distinct diseases caused by mutations in separate independent genes, Cdkl5 and 
methyl CpG binding protein 2 (MeCP2) respectively. While in vitro data suggested that the two might 
interact (1, 51, 52), functional interaction in vivo remains unclear. 
Recently, genes such as MeCP2 and CaMKIIα, which have been implicated in the pathogenesis of 
ASD (53-55), and that are highly expressed in the CNS, have also been localized to the peripheral 
nervous system where they regulate sensory modalities (40, 56). However, a role in nociception had 
not been described so far.  
Limitations of our work include the need for future comprehensive clinical and neurophysiological 
investigation to fully characterize pain perception in CDD patients as well as for the assessment of 
potential additional Cdkl5-dependent mechanisms that might control pain perception and nociception.  
Additionally, it is presently not known whether Cdkl5 plays a role in inflammatory or in traumatic 
painful conditions or whether reduced epidermal innervation is directly responsible for impaired 
nociception. Lastly, while impairment in epidermal innervation only occurred in adult mice, the human 
clinical data includes infants and toddlers. Published evidence suggests that skin innervation is already 
complete approximately at 1.5 years of age (57), however it would be useful to generate data allowing 
for a direct comparison between the maturation of skin innervation in humans and mice.  
In summary, the importance of these findings lies on the (i) identification of a previously unrecognized 
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regulatory mechanism for nociception that relies on Cdkl5, the (ii) discovery of impaired nociception 
as a previously uncharacterized symptom in CDD and (iii) the usefulness of nociception as therapeutic 
outcome measure in animal models of CDD. Since animal models of CDKL5 deficiency do not develop 
seizures, monitoring pain responses during therapeutic interventions might be a unique opportunity to 
test novel disease-modifying treatment in pre-clinical before clinical settings. Lastly, our data suggest 
that gene therapy or other interventions in CDKL5 patients should not only be directed to the brain but 
also to dorsal root ganglia to restore nociceptive input in patients with impaired pain perception.  
 
Normal: individuals with normal pain sensitivity; reduced or enhanced: individuals with reduced or enhanced pain sensitivity 
n, number of individuals; RR, risk ratio; RRR, relative risk ratio; CI, confidence interval; Ref, reference category 
Note: excluded individuals where both reduced and enhanced sensitivity were reported 
* including missense/in-frame mutations within catalytic domain and TEY motif 
 
Table 1. Associations between pain sensitivity, gender, age group and mutation type in 202 individuals 
with confirmed CDKL5 mutation.  
 
Research Design and Methods 
Study design 
We investigated the role of Cdkl5 in nociception in both human and murine sensory neurons as well as 
in Cdkl5 mutant mice by performing both mechanistic and behavioral studies. 
Questionnaire 




All animal procedures were approved by Imperial College London ethic committee and were 
performed in accordance with the UK Animals Scientific Procedures Act (1986). C57Bl/6 background 
mice lacking Cdkl5 exon 6 (4) and Cdkl5 floxed C57Bl/6 background mice containing loxP sites 
flanking Cdkl5 exon 4 (12) and wild-type littermates or C57Bl/6 (Harlan, UK) mice ranging from day-
4 to day-70 of age were used for all experiments. Mice were anaesthetized with isoflurane (3% 
induction, 2% maintenance) and buprenorphine (0.1 mg kg−1) and carprofen (5 mg kg−1) were 
administered peri-operatively as analgesic. The experimenter was blind to the genotype of animals and 
to treatment given to each animal.  
Epidermal innervation 
Following euthanasia, the external skin of the mouse foot was sterilized with ethanol and a skin punch, 
1 mm in diameter, was introduced perpendicularly to the surface of pad skin, rotated and advanced 
until reaching 1-2 mm depth (58). The specimens were immediately fixed in 3% paraformaldehyde, 
75mM Lysine hydrochloride (Sigma L5501), 2.2mg/ml Sodium Metaperiodate (Sigma S1878) for up 
to 24 hours at 4 °C, and then kept in a cryoprotective solution overnight. After fixation, the tissue was 
serially cut (sections of 50 μm in thickness, perpendicular to the dermis) using a freezing microtome. 
The slices were then treated with blocking solution for two hours at RT (PBS – Triton X-100 0.3% - 
Donkey Serum 10%) and exposed to different primary Abs. βIII-Tubulin (Abcam ab-18207) and 
Collagen IV (Sigma C1926) were the markers used to assess, respectively, the density of IENF and the 
basal lamina. Using confocal microscopy (Leica TCS SP5 II or Zeiss LSM-780 inverted confocal 
microscope), individual IENF crossing the dermal–epidermal junction were counted and the 
intraepidermal network length was analyzed by using Neuron-J software (magnification X20) in at 
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least three non-consecutive sections (59). For anti-PGP9.5 immunohistochemistry, sections were 
immunostained by using Vectastain ABC kit (PK-4001) with minor adjustments. Endogenous 
peroxidase was blocked by incubation in PBS/0.1% Tx100 containing 0.3% hydrogen peroxide for 10 
min. After 2x PBS washes, sections were blocked in normal blocking serum for 20min and incubated 
with primary Ab (anti-PGP 9.5, Ultraclone, 1:20000, gift from Prof. Praveen Anand) overnight at R.T. 
After washing, sites of primary Ab binding were revealed by biotinylated secondary anti-rabbit 
incubation followed by avidin–biotin peroxidase reaction, using Impact DAB as substrate (SK-
4105). Sections were counterstained for nuclei in Mayer’s Haematoxylin, dehydrated with serial 
incubations of ethanol:  70% (1x, 2min); 90% (1x, 2min); 100% (2x, 5min), and mounted in xylene-
based mounting medium. 
Murine DRG, Spinal Cord and Sciatic Nerve Immunohistochemistry 
After euthanasia, the tissues were removed and fixed in 4%-PFA-PBS for up to 24 h at 4 °C, and then 
kept in a cryoprotective solution overnight. After fixation, the samples were cut (thickness 15 μm) 
using a freezing microtome. Immunohistochemistry on tissue sections was performed according to 
standard procedures. For all antibodies used, the samples were blocked for 1 h with 10% Donkey Serum 
- 0.3% PBS–Triton-X100, and then incubated with Cdkl5 (rabbit, Sigma HPA002847, 1:100), CGRP 
(mouse, abcam ab81887, 1:100), IB4 (Thermo-Fisher I21411Alexa Fluor™ 488 Conjugate, 1:250), 
Parvalbumin (mouse, abcam ab64555, 1:100), TRPV1 (guinea pig, Thermo-Fisher PA1-29770, 1:100), 
NF200 (mouse, N5389, Sigma Aldrich), CaMKIIα (mouse, Thermo-Fisher MA1-048, 1:100), 
phospho-Thr286-CaMKIIα (mouse, Thermo-Fisher MA1-047, 1:100), phosphor-Thr202/Tyr204-
Erk1/2 (rabbit, Cell Signaling #9101, 1:100); βIII-Tubulin (rabbit, abcam ab18207, 1:500) antibodies 
at 4 °C overnight. Subsequently, samples were incubated with AlexaFluor-conjugated goat secondary 
antibodies according to standard protocols (Invitrogen). For triple immunostaining: 15 µm slides 
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incubated with primary antibodies CDKL5 anti rabbit 1:100, TRPV1 anti guinea pig 1:100, CamKIIa 
anti mouse 1:100 (secondary antibodies: Alexa 647 anti rabbit 1:1000, Alexa 594 anti mouse 1:1000, 
Alexa 488 anti guinea pig 1:100). All tissue sections were counterstained with Hoechst (Molecular 
Probes). 
Differentiation of iPSC Derived Nociceptors  
iPSC lines from four CDKL5 patients, carrying different mutations (E55fsX74, G155fsX197, Q347X, 
S855X; special gift from Prof. N. Mazarakis, Imperial College London, and Dr. D. Millar, Cardiff 
University), were cultured in Matrigel coated wells (Corning Membrane Matrix 354234) and 
mTeSRTM1 medium (STEMCELL Technologies) supplemented with the ROCK inhibitor Y27632 
10μM (STEMCELL Technologies). When a confluency of 60-70% was reached, we started the 
differentiation by using five inhibitors for 10 days (LDN193189 100nM, SB431542 10μM, 
CHIR99021 3μM, SU5402 10μM, DAPT 10μM; STEMCELL Technologies) in hESC medium 
(DMEM-F12, knockout serum replacement 20% (Gibco), L-Glut 1mM, MEM non-essential amino 
acid solution (M7145 Sigma) (60). The cells were then grown in Neuronal Growth Medium (DMEM-
F12, HI-FBS 10%) supplemented with neurotrophins (BDNF 10ng/ml, NGF 10ng/ml, NT3 10ng/ml, 
GDNF 10ng/ml; STEMCELL Technologies) and ascorbic acid (35ng/ml; 72132 STEMCELL 
Technologies) for 4 days and treated with mitomycin C (1μg/ml; 73272 STEMCELL Technologies) 
for 3 hours. Lastly, the cells were grown for 30 days and replated 1 day before the calcium imaging 
experiment. The expression of neuronal markers (βIII-Tubulin and CGRP for nociceptors) was 
monitored at days 0, 7 and 12, as well as at day 42, when we confirmed their sensitivity to 50mM KCl 
and 500ng/ml capsaicin. Cells were fixed with 4% PFA – 4% sucrose and the immunocytochemistry 
was performed by incubating fixed cells with βIII-tubulin (Abcam ab18207) and CGRP (Abcam 
ab81887) antibodies at 4°C overnight. This was followed by incubation with AlexaFluor-conjugated 
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goat secondary antibodies according to standard protocols (Invitrogen). All cells were counterstained 
with Hoechst (Molecular Probes). 
Western Blot analysis of skin, brain, DRG and sciatic nerve lysates 
Approximately 10-30 μg of protein extracts (lysis buffer: 50 mM Tris-HCl, pH 7.4, 150mM NaCl, 
Nonidet P-40 1%, 1 mM EDTA, 0.5 mM DTT, protein inhibitor cocktail Sigma, 1 mM PMSF; lysed 
for 30 min on ice followed by 15 min centrifugation at 4°C) from brain, DRG, sciatic nerve and skin 
were heated at 95°C and separated by 8% SDS–polyacrylamide gel electrophoresis (PAGE) gels 
(37.5:1 acrylamide:bis-acrylamide) and transferred to nitrocellulose membranes for 2 h. Before gel 
loading, protein concentration was quantified using Pierce BCA Protein Assay Kit (ThermoScientific). 
Membranes were blocked with 5% BSA or milk for 1 h at room temperature and incubated with Cdkl5 
(Sigma HPA002847, 1:1000), CaMKIIα (AvivaSysBio Ab286 OAECOO614, 1:1000), CGRP (Abcam 
ab-189786, 1:1000), PGP9.5 (Abcam ab-8189, 1:1000), βIII-tubulin (Abcam ab-18207, 1:1000), 
Gapdh (Cell Signaling #2118) antibodies at 4°C overnight. Following HRP-linked secondary antibody 
(GE Healthcare) incubation for 1 h at room temperature, membranes were developed with ECL 
substrate (GE Healthcare) (ThermoScientific) and the bands detected with a CCD camera (Syngene, 
GeneGnome XRQ) and analyzed, after subtraction of the background, by using the ImageJ software. 
RNA isolation and RT-PCR Analysis  
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's 
instructions. Contaminating DNA was removed with DNaseI (Invitrogen 1734510), and the obtained 
RNA was quantified with a NanoDrop UV Visible Spectrophotometer; the quality of the RNA was 
assessed through agarose gel electrophoresis. cDNA was synthetized from 200 ng of RNA using the 
SuperScript First Strand reverse transcriptase kit (Invitrogen 1933910) as indicated by the 
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manufacturer. The RT-PCR was performed in 20 μl using 50 ng of cDNA and the following cycling 
parameters: Cdkl5-Ex6 and Gapdh, 35 cycles, 95 °C 1m, 54 °C 30s, 72 °C 1m.  
Injection of viral vectors into the sciatic nerve 
2.5 µl of each viral vector (AAV5-GFP SignaGen SL100819 or AAV5Cre SignaGen SL100821, titer 
3.06X1013 GC/ml) was injected into the sciatic nerve of adult Cdkl5-floxed mice (12) with a 
Hamilton syringe and Hamilton needle (NDL small RN ga34/15mm/pst45o). After 2 months, the 
animals were exposed to specific behavioral tests and then sacrificed, to evaluate the silencing 
of Cdkl5gene in sciatic DRG by WB. 
Mechanical Allodynia Test 
Mechanical allodynia was quantified by measuring the hind paw withdrawal response to von Frey 
filament stimulation. Animals were placed in methacrylate cylinders (20 cm high, 9 cm diameter) with 
a wire grid bottom through which the von Frey filaments (North Coast Medical, Inc., San Jose, CA) 
with a bending force in the range of 0.16-8g were applied by using a modified version of the up–down 
paradigm, as previously reported(61).  The filament of 0.16g was used first and the 8-g filament was 
used as a cut-off. Then, the strength of the next filament was decreased or increased according to the 
response. The threshold of response was calculated using a regression curve generated based on the 
sequence of filament number (numbered from 1 to 9) versus log(10) of their strength in gr, an 
interpolation of the number of filament plus or minus a correction factor of 0.5 according to the 
response was then used to calculate the threshold of response in gr. Clear paw withdrawal, shaking, or 
licking of the paw was considered as a nociceptive-like response. Both hind paws were tested and 
averaged. Animals were allowed to habituate for 1 h before testing in order to allow an appropriate 
behavioral immobility. 
Hargreaves Test (Plantar Test) 
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Thermal hyperalgesia was assessed as previously reported by Hargreaves et al.  Paw withdrawal 
latency in response to radiant heat was measured using the plantar test apparatus (Ugo Basile, Varese, 
Italy). Briefly, the mice were placed in methacrylate cylinders (20 cm high × 9 cm diameter) positioned 
on a glass surface. The heat source was positioned under the plantar surface of the hind paw and 
activated with a radiant light beam, the intensity of which was chosen in preliminary studies to give 
baseline latencies from 8 to 9 s in control mice. A cut-off time of 15 s was used to prevent tissue 
damage in the absence of response. The mean paw withdrawal latencies from both hind paws were 
determined from the average of five separate trials, taken at 2-min intervals to prevent thermal 
sensitization and behavioral disturbances. Animals were habituated to the environment for 1 h before 
the experiment to become quiet and to allow testing (62). 
Grid walk 
Mice were allowed to run the grid walk (50 × 5 cm plastic grid (1 × 1 cm) placed between two vertical 
40-cm-high wood blocks) three times per session. The total number of steps and missteps per run for 
each hindpaw was analyzed by a blinded investigator. 
Adhesive removal 
Small adhesive stimuli (6-mm round adhesive labels) were placed on both hindpaws of the mouse, the 
time to make first contact with both forepaws, as well as the time to completely remove the adhesive 
were recorded for each paw. Each mouse underwent three trials. All testing was performed by a blinded 
investigator, after a period of acclimatization.  
Thermal Place Preference Test 
Unrestrained mice were allowed to move freely between two connected plate compartments (Ugo 
Basile) each set at a given temperature, thus choosing their preferred temperature environment. Mice 
were placed on one plate set to 30oC, which is known to be a thermoneutral temperature for mice while 
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the other plate was set to either neutral 30oC or non-noxious temperatures of either 23 or 37oC. Each 
animal was monitored for 10 minutes, recording the time spent in each plate compartment. Each 
temperature range was tested at the same time of day on each testing day, randomly interchanging plate 
compartments to avoid environmental bias. All testing was performed by a blinded investigator, after 
a period of acclimatization. 
Cdkl5 immunoprecipitation  
The cortex of three mice (P65) was removed and immediately lysed in lysis buffer (Tris-HCl 7.5 
20mM, NaCl 150mM, EDTA 1mM, EGTA 1mM, Triton X-100 0.1%, PIC Sigma P8340-1x, 1mM 
DTT, PhosSTOP Sigma P0044-1x) on ice (glass pestle Thermo-Fisher FB56679) and centrifuged 
(14000g 15m). The protein concentration was determined by the Bradford method. For each sample, 
1mg of protein was treated for 30m with 500U Benzonase (E1014 Sigma) at 37°C, then exposed 
(overnight wheel, 4°C) to 1μg of Cdkl5-Ab (Sigma HPA002847) or 1μg Rabbit IgG (Jackson 
011000003 lot95014). Magnetic beads (40μl 50% Dynabeads Protein G 10003D, Life Technologies) 
were subsequently added to the samples, and the mixture was further incubated on the wheel for 2hrs 
at 4°C. The beads were washed three times (3x20m washes with lysis buffer, wheel 4°C) and proteins 
were eluted by boiling for 10 min in NuPage Sample Reducing Agent - DTT (30μl, Thermo-Fisher 
NP0009; 80°C) and loaded on a 8% SDS-PAGE or analyzed by Mass Spectrometry. 
Mass Spectrometry Sample Preparation 
Samples were boiled at 70°C for 10 minutes in 1x NuPAGE LDS Sample Buffer (Life technologies) 
containing 100mM DTT and separated on a 10% NuPAGE Bis-Tris gel (Life technologies) for 10 at 
180V in MES running buffer (Life technologies). After fixation in 7% acetic acid containing 40% 
methanol and subsequently staining for 30 minutes using Colloidal Blue staining kit (Life technologies) 
protein lane was excised from the gel, chopped and destained (50% ethanol in 25 mM NH4HCO3) for 
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15 minutes rotating at room temperature and dehydrated for 10 minutes rotating in 100% acetonitrile. 
Vacuum dried samples were rehydrated and reduced for 60 minutes in reduction buffer (10mM DTT 
in 50mM NH4HCO3 pH 8.0) at 56°C and subsequently alkylated in 50 mM iodoacetamide in 50mM 
NH4HCO3 pH 8.0 for 45 minutes at room temperature in the dark. Dehydrated and vacuum dried 
samples were trypsin digested (1µg trypsin/sample in 50mM Triethylammonium bicarbonate buffer 
pH 8.0) at 37°C overnight. Stepwise peptide extraction was done as follows: twice extraction solution 
(30% acetonitrile) and 100% acetonitrile for 15 minutes at 25°C shaking at 1400 rpm. Reductive 
methylation for quantification was performed as described in Hsu et al. (2003) (63). For Cdkl5 
immunoprecipitation, peptides were labelled LIGHT (DimethLys-0 and DimethNter0) and control IgG 
immunoprecipitation peptides labelled HEAVY (DimethLys-4 and DimethNter4). Afterwards they 
were mixed 1:1 and further processed. In the so called “reverse” experiment Cdkl5 IP peptides were 
labelled HEAVY and control IgG IP peptides were labelled LIGHT. We performed Cdkl5 IP 
experiments in duplicates for each of the three different animals resulting in n=6. After purification 
and desalted using C18 stage tips (Empore) (64) 3.5 µL peptides were loaded and separated on C18 
column (New Objective) with 75 µm inner diameter self-packed with 1.9µm Reprosil beads (Dr. 
Maisch) which was mounted to an EasyLC1000 HPLC (Thermo-Fisher Scientific).  
Mass Spectrometry Measurement and Data Analysis 
Reversed-phase chromatography gradient (Buffer A: 0.1% formic acid, Buffer B: 80% acetonitrile and 
0.1% formic acid, Gradient: 0-67 min 0-22% Buffer B, 67-88 min 22-40% Buffer B, 89-92 min 40-
95% Buffer B) was applied and peptides eluted and directly sprayed into a Q Exactive Plus mass 
spectrometer from Thermo-Fisher Scientific operating in positive scan mode with a full scan resolution 
of 70,000; AGC target 3x10^6; max IT = 20ms; Scan range 300 - 1650 m/z and a Top10 MSMS 
method. Normalized collision energy was set to 25 and MSMS scan mode operated with resolution of 
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17,000; AGC target 1x10^5; max IT = 120 ms. Triggered MSMS masses were excluded dynamically 
for 20 seconds. Database search was performed using MaxQuant Version 1.5.2.8 (65) against Mus 
Musculus Uniprot database (downloaded 8th January 2018; 53819 entries) with Trypsin/P as digestion 
enzyme allowing 2 missed cleavages. As settings the following was applied: variable modification: 
Acetyl (Protein N-term); Oxidation (M), fixed modifications: Carbamidomethyl (C), FDR of 1% on 
peptide and protein amount was applied. As light label: DimethylLys0 and DimethylNter0 and heavy 
label: DimethylLys4 and DimethylNter4 were set with max. 3 labeled amino acids. Proteins with at 
least two unique peptides were considered as identified. Proteins matching reverse database or common 
contamination list as well as proteins with peptides only identified by peptides with modification were 
filtered out. Statistical calculation and visual presentation were done in R version 3.5.1 (released 2nd 
July 2018; R Core Team (2016) R: A language and environment for statistical computing R: 
Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/). Protein 
ratios of each immunoprecipitation experiment (n=6) were divided by median to normalized ratios. 
The new obtained median was 1. All “reverse” replicates were inverted to obtain, positive values for 
IP enrichment. Log2 transformed median normalized ratios were plotted as box plot (function “ggplot“, 
package “ggplot2“). For each individual protein depicted in the box plot a parametric Two-tailed tests 
was performed (function “compare_means”, package “ggpubr”) against all other measured proteins. 
Significance was calculated and indicated (*P<0.05 **P<0.01 ***P<0.001 ****P<0.0001). Further 
packages used: “openxlsx”, “dplyr”, “reshape”. These studies were performed in the proteomics 
facility in Mainz, Germany. 
DuoLink Proximal ligation Assay  
After blocking DRG slices (50μm of thickness), from P65 C57Bl/6 Cdkl5 null mice and wild-type 
littermates with Duolink Blocking Solution, primary antibodies raised in two different species, specific 
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for the two proteins of interest (rabbit-Cdkl5 Sigma HPA002847 and mouse-CaMKIIα Thermo-Fisher 
MA1-048), were added to the tissue samples (1:100) and incubated in a humidity chamber overnight 
at 4°C. After washing, according to the manufacturer protocol (PLA; Sigma DUO92101), the samples 
were then incubated with secondary antibodies coupled to oligonucleotides (proximity probes) for 1 
hour at 37°C and exposed to the ligase for 30 minutes at 37°C; the DNA polymerase was lastly added 
for 100 minutes at 37°C. The slides were washed thereafter, mounted and analyzed at the Leica TCS 
SP5 II confocal microscope (63x magnification; 6 non-consecutive 38μm-sections from the entire 
DRG). Each DRG was cut throughout and 6 slices (1 out of 3) was used for immunolabelling 
experiments; imaging was carried out with the Leica TCS SP5 II confocal microscope. The number of 
PLA+ neurons per mm3 was counted.  
DRG culture 
Adult DRG were dissected and collected in Hank’s Balanced Salt Solution (HBSS) on ice and 
digested according to standard procedures. Cultures were maintained in medium containing B27 
and penicillin–streptomycin in DMEM:F12. Cells were plated on coated glass coverslips 
(0.01 mg ml−1PDL) for 48-72 h and fixed with 4% PFA–4% sucrose. Immunocytochemistry was 
performed by incubating fixed cells with Cdkl5 (Sigma HPA002847), βIII-tubulin (Abcam 
ab18207), CaMKIIα (Thermo-Fisher MA1-048), (Abcam ab81887), Parvalbumin (Abcam ab555), 
GFP (Thermo-Fisher A-6455), HA (Abcam ab18181) antibodies at 4 °C overnight. This was 
followed by incubation with AlexaFluor-conjugated goat secondary antibodies according to 
standard protocols (Invitrogen). All cells were counterstained with Hoechst (Molecular Probes).  
DRG explants 
DRG from adult WT and Cdkl5 null mice were isolated, plated on a culture dish and incubated in 
Ca(2+) dye Fluo-4AM (Thermo-Fisher F14201 494/506nm; 1μM) in HBSS (with 20mM Hepes pH7.4  
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and 1μl/ml pluronic F127 P3000MP, Life Technologies) for 30m at 37°C. After washing in HBSS-
Hepes, the DRG were placed on the surface of polystyrene-plates, perfused with a small amount of 
“basal medium” (2ml/m: NaCl 160mM, KCl 2.5mM, CaCl2 1mM, MgCl2 2mM, Hepes pH7.4 10mM, 
glucose 10mM; 37°C) and stimulated for 20s with capsaicin (Tocris0462 500ng/ml). Live-imaging was 
acquired by Nikon Eclipse-TE-2000U microscope (20x magnification) and analyzed by ImageJ (Fluo-
4 signaling: increased fluorescence emission at 506nm).  
DRG culture infection and treatments 
WT and Cdkl5 null DRG-neurons seeded at a density of 5,000 cells/cm
2 
were infected with AAV9 
viral particles (AAV9-Ctrl-ss-pTR-CBh-GFP-stuffer; AAV9-ss-pTR-CBh-HA-CDKL5107) 24 h after 
plating (100,000 virus genomes (VG)/cell) (66). Microscopic analysis was carried out 24 h post 
transduction with a Nikon Eclipse-TE-2000U microscope (20x magnification, bright-field phase 
contrast or GFP-488nm). 24, 48 and 72 hrs after plating, the neurons were treated with KN92, KN93 
(0.5μM, Tocris 4130 and 1278) or DMSO alone (67). 72 hours after the treatment or the infection, the 
respective efficacy of KN93 and AAV9 particles was investigated (phospho-CaMKIIα and Cdkl5-
protein expression). Cdkl5-protein Expression Analysis: 72 hrs after the treatment, the medium was 
removed and the cultures were scraped into RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
NP-40, 0.5% deoxycholate, protease and phosphatase inhibitors cocktails Sigma) and centrifuged at 
14000g for 15 min at 4°C to remove cell debris. The supernatant was transferred to a new tube, mixed 
with Laemmli sample buffer (2x), boiled at 95°C for 5 min and loaded on SDS-PAGE (incubation with 
Cdkl5 (Sigma HPA002847, 1:1000) and βIII-tubulin (Abcam ab-18207, 1:1000) antibodies). For 
analysis of the phospho-CaMKIIα: 72 hrs after the treatment, the wells were fixed and processed with 
anti- phospho-Thr286-CaMKIIα (mouse, Thermo-Fisher MA1-047, 1:100) and βIII-tubulin 
(rabbit, abcam ab18207, 1:500) antibodies, as previously described. 
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GFP+ neuron sorting and RT-PCR 
For nerve injection of AAV1-CMV-GFP (Tebu-bio), after nerve exposure, 2.5 microliters of viral 
particles were injected with a Hamilton syringe slowly, and mice were used after 4 weeks to allow 
complete GFP expression. DRG were collected in Hank’s balanced salt solution (HBSS) on ice and 
dissociated in DMEM (Invitrogen) containing 5mg/ml Dispase II (Sigma), 2.5mg/ml Collagenase Type 
II (Worthington), 1 mg/ml papain (Sigma) at 37°C for 30 mins with occasional mixing. Subsequently 
DRG were transferred to medium containing 10% heat inactivated FBS (Invitrogen), 1X B27 
(Invitrogen) in DMEM:F12 (Invitrogen) mix and were manually dissociated by pipetting to 
disaggregate clumps. After filtering with a 70 micron strainer, the cell suspension was mixed with a 
9%  Percoll gradient (Sigma) and centrifuged at 800g x 12 min to remove tissue debris (similar 
to https://www.jneurosci.org/content/27/10/2435#sec-2).  The cell suspension was run through a 
130 μm nozzle at low pressure on a BD FACS Aria II machine to collect GFP positive neurons. RNA 
extraction was performed via Qiagen mini kit, following manufacture’s protocol (as described in 
Arnau’s paper).  cDNA was synthesized from 0.5 μg of total RNA using both oligodT and random 
hexamers from the SuperScript II Reverse Transcriptase kit (Invitrogen) and PCR was performed using 
15 ng of cDNA using the following program: 95C 5min, 30 cycles of 94: 30sec/54 30sec/72 1 min 
followed by extension at 72: 10min. 
The forward (F) and reverse (R) primers were:  
mCdkl5-Ex6-Fw, 5’-GGAGACGACCTTACGAGAGC 
mCdkl5-Ex6-Rv, 5’-GGACGATGTCGTTCTTGTGG 
mGapdh F, 5’-AAGGTCGGTGTGAACGGATTTG 
mGapdh R, 5’-GCAGTGATGGCATGGACTGTG 
mGapdh F2, 5’-GAACATCATCCCTGCATCC 
mGapdh R2, 5’-CAGTGTAGCCCAAGATGCCC 
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mNeurofilament F, 5’-TCAAGTGCGACGTGACGTCG 
mNeurofilament R, 5’-AGTCGGTCCAACCTCACTCG 
mGFAP F, 5’-CACGAAGCTAACGACTATCGC 
mGFAP R, 5’-AGTGCCTCCTGGTAACTGGC 
 
DRG cultures overexpressing AIP (CaMKII inhibitor)  
Adeno-associated viral particles (AAV8) carrying pAAV-CMV-EGFP or EGFP-AIP plasmid (AIP, 
Autocamtide-2-related-inhibitor peptide: KKALRRQEAVDAL) were employed.  WT and Cdkl5 
mutant null DRG-neurons were seeded at a density of 5,000 cells/cm2 and infected at DIV1 with AAV8 
viral particles, carrying EGFP or EGFP-AIP (50,000 virus genomes (VG)/cell), and AAV9 viruses 
expressing GFP or human CDKL5107  (AAV9-Ctrl-ss-pTR-CBh-GFP-stuffer; AAV9-ss-pTR-CBh-
HA-CDKL5107; 50,000 virus genomes (VG)/cell) (40). 72 hours after plating, the respective efficacy 
of AAV8 and AAV9 particles was investigated (phospho-CaMKIIα and CDKL5-protein expression), 
as previously described. 
Neurite outgrowth analysis 
Immunofluorescence was detected using a Nikon Eclipse-TE-2000U microscope at 20× 
magnification using a CDD camera (scMOS camera QImaging). Five fields per coverslip were 
included in the analysis. At least 30 cells per coverslip were measured. Total neurite length was 
measured and normalized to the number of cells. All analyses were performed blinded. Neurite 
analysis and measurements were performed using the Neuron-J plugin for ImageJ.  
Image analysis for immunohistochemistry and immunocytochemistry 
Photomicrographs were taken with Nikon Eclipse-TE-2000U microscope at 20× magnification. 
Alternatively, for confocal imaging, a Leica TCS SP5 II or a Zeiss LSM-780 inverted microscope (z-
stacks, slice spacing 1.65μm) were used at 20× or 63x magnification. DRG, spinal cord and sciatic 
nerve micrographs were processed with the software ImageJ: a constant fluorescence intensity 
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threshold was set across each cell (or area) in control-tissues. On the basis of this threshold, for each 
cell (or area) in the samples, the intensity of pixels was calculated in each channel. This was done in 
triplicate and the investigator was blinded to the experimental group. 
Single-cell calcium imaging  
We assessed changes in the intracellular Ca2+ concentration ([Ca2+]i) using conventional ratiometric 
imaging in cultured DRG neurons isolated from WT and CDKL5-/y mice. Briefly, after loading with 
1μM Fura-2 (Invitrogen), the cells were exposed to capsaicin (500ng/ml) for 20 seconds and then to 
50mM KCl (20 seconds) in (in mM) NaCl 160, KCl 2.5, CaCl2 1, MgCl2 2, Hepes 10, glucose 10 
(pH7.4; 37°C) with a flow rate of ~2ml/min. Recordings, with 355nM and 380nM excitation and at 
0.5Hz, were done with the WinFluor (J Dempster, Strathclyde University), and analyzed using the 
Clampfit (Invitrogen), software packages. Measurements were repeated at least in 3 independent 
cultures with analyzing ~100 cells in each condition. Responses of CDKL5-/y neurons were normalized 
to those of WT cells (68).  
Intradermal injection of capsaicin 
Capsaicin (10 μl) [0.1 g/ml−1 100% ethanol; 1:1000 in PBS, 0.5% Tween 80, 10% ethanol] or vehicle 
(PBS, 0.5% Tween 80, 10% ethanol) was administered via intraplantar injection (69) to adult WT and 
Cdkl5 mutant mice or to adult Cdkl5-Floxed mice treated, two months before, with AAV5-GFP or 
AAV5-GFP-CRE (intra-sciatic injection). After capsaicin injection, the licking time was measured 
during the first 3 minutes. Finally, WT vs Cdkl5 null adult mice were sacrificed to study the activation 
of the peripheral pain pathways in fixed sciatic DRG and spinal cord. Immunohistochemistry on DRG 
and spinal cord sections was performed by using anti-phospho-Thr286-CaMKIIα (mouse, Thermo-
Fisher MA1-047, 1:100), or anti-phospho-Thr202/Tyr204-Erk1/2 (rabbit, Cell Signaling 
#9101, 1:100).  
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HEK-293 Cell Transfection, CDKL5-Immunoprecipitation and Kinase Assay 
HEK-293 cells were cultured on D-Poly-lysine in 60mm plates (DMEM Gibco, 0.7% glucose, 10% 
Fetal Bovine Serum, 200mM glutamine with 1% Penicillin/Streptomycin solution). After reaching 
85% confluency, the cells were co-transfected with Lipofectamine vesicles (Thermo-Fisher L3000001 
Lipofectamine-3000) containing two target DNA: pcDNA5-FRT/TO-C-3FLAG expressing rat-
CAMKIIα and human-CDKL5 (or, alternatively, human-CDKL5-K42R); the control cells were treated 
with only Lipofectamine. The target plasmids (1ug per sample) and 15 μl Lipofectamine were added 
to the transfection medium Opti-MEM Gibco, left at room temperature for 15 minutes, to enable the 
transfer of plasmids into the vesicles, and then added to the HEK cells (incubation: 4 hours at 37°C). 
Finally, the transfection medium was replaced with definitive medium for three days. The cells were 
collected directly in 1ml of Lysis Buffer (20mM pH 7.4 Hepes, 150mM NaCl, 0.1% NP40, PIC Sigma 
P8340-1x, 1mM DTT, PhosSTOP Sigma P0044-1x), sonicated (1 min) and then centrifugated at 
10000g (5 min, 4°C). The protein concentration of the supernatant was determined by the Bradford 
method and the CDKL5 Immunoprecipitation was performed as described (“Cdkl5 
Immunoprecipitation”). To confirm the overexpression of the kinases, the 5% of the supernatant was 
directly loaded on SDS-PAGE. The kinase activity of CDKL5 was simultaneously verified using the 
supernatant of the lysate from plates overexpressing CDKL5 or its inactive form CDKL5-K42 (Kinase-
Dead), exposed to Anti-Flag Beads (Sigma M2 Magnetic Beads; 2 hours, wheel 4°C). The beads were 
then washed three times (wheel 4°C, 20min) in Lysis Buffer, resuspended in Kinase Buffer-1x 
(Thermo-Fisher PV3189) and added to a mixture of 32P-ATP (1mM) and cold-ATP (1mM). After 
incubation (30 minutes at 30°C), the elution was performed by using Laemmli 6x (30 μl, 70°C, 3 min) 
and the samples were loaded on SDS-PAGE. The gel, fixed in methanol 2% (1 hour, RT), was dried 
(80°C, 2 hours) and exposed to an X-ray film for two days. 
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Statistics and reproducibility 
 Data are plotted as mean ± S.D. or S.E.M. All experiments were performed in triplicate unless 
specified. Asterisks indicate a significant difference analyzed by ANOVA with Tukey or Sidak post 
hoc test, Student’s t-test as indicated for normal distributions, parametric Two-tailed test and Fisher’s 
combined probability test. All data analysis was performed blinded to the experimental group. 
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Figure 1. Cdkl5 is expressed in nociceptors. A. Cdkl5-immunostaining in DRG from WT and  
Cdkl5-/y mice (20x, Nikon Eclipse-TE-2000U microscope). L-I-S: insets show high magnification of 
large, intermediate and small diameter DRG neurons. B. Graphs showing ratio of signal intensity 
between WT and Cdkl5-/y three neuronal subpopulations. N: 3 mice each, Mean with SD, Student’s t-
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test, **P<0.01 *P<0.05. C. Graphs showing percentage of Cdkl5+ positive neurons in the indicated 
sizes. N:3 mice each. D. Confocal immunofluorescence images of DRG biopsies from P70 WT mice 
showing the co-expression of Cdkl5, CGRP, IB4, Parvalbumin and NF200 (20x images from Zeiss 
LSM-780; yellow arrowheads: co-expression; white arrow heads: expression of Cdkl5 or individual 
cell type markers only). E. Percentage of Cdkl5+ cells co-expressing each neuronal marker (average 
percentage values represent average from 3 independent mice). F. Percentage of Parvalbumin+, IB4+, 
CGRP+ or NF200+ cells co-expressing Cdkl5+ (average percentage values represent average from 3 
independent mice). G. CDKL5 and CGRP immunostaining from isogenic iPS derived neurons after 0, 
7 and 12 days of differentiation into nociceptors (63x, Leica TCS SP5II). H. Graphs showing the 
percentage of CDKL5+ cells and CDKL5+ neurons coexpressing CGRP at different stages of 
differentiation. N: 3, Mean with SD, One-way ANOVA, Tuckey’s post-hoc, ****P<0.0001  
***P<0.001. 
 
Figure 2. Conditional knockdown of Cdkl5 impairs nociception. A. Schematic illustrating 
conditional knockdown of Cdkl5 in DRG neurons. Depicted is the injection of AAV5 particles into the 
sciatic nerve of 12 weeks old Cdkl5-floxed mice. B. Immunoblotting showing strongly reduced 
expression of Cdkl5 from bilateral sciatic DRG (pool of 4 mice) 8 weeks after AAV5-GFP or AAV5-
GFP-cre. βIII-tubulin has been used as loading control. C. Graph showing the conditional knockdown 
of Cdkl5 in DRG (Cdkl5-floxed mice) after GFP-AAV5 vs CRE-AAV5 injection in the sciatic nerve 
(N=3, Mean with S.E.M., Student’s t-test, ***P<0.001). D-G. Behavioral assessment of pain 
sensitivity with Hargreaves (thermal nociception; Paw withdrawal latency) and von Frey 
(mechanical allodynia; Paw withdrawal threshold) shows significantly reduced sensitivity in Cdkl5 
conditionally deleted (E, F) as well as in Cdkl5-/y mice (E, G). D, F. N:10 mice, Mean with SD, 
Student’s t-test, ****P<0.0001  ***P<0.001. E,G. N: 7 WT vs 6 Mut mice, Mean with SD, Student’s 
t-test, **P<0.01 *P<0.05. H. Graph showing no difference in the reaction time (time to contact and 
time to remove the adhesive tape from the paw) in Cdkl5 DRG conditionally deleted (cKO) vs control 
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GFP injected mice. N:10, Mean with SD, Student’s t-test, P>0.05. I. Graph showing no difference in 
the number of posterior foot slips in each run on a Gridwalk in Cdkl5 DRG conditionally deleted 
(cKO) vs control GFP injected mice. N: 10 mice per group, Mean with SD, Student’s t-test, P>0.05.  
 
Figure 3.  Coexpression of Cdkl5 with CaMKIIα and TRPV1. A. Confocal microscopy of 
immunofluorescence showing co-expression of Cdkl5, CaMKIIα and TRPV1 (magnification 20x, 
Leica TCS SP5II; yellow arrowheads: co-expression; white arrowheads: expression of Cdkl5 or 
individual cell type markers only). B. Average diameter and SD of each Cdkl5+, CaMKIIα+ or 
TRPV1+ population of cells (average values from 3 independent mice). C. Percentage of Cdkl5+ or 
CaMKIIα+ cells co-expressing each marker (average percentage values represent average from 3 
independent mice. Cdkl5+ cells coexpressing CaMKIIα: 79.07+/-1.56%; Cdkl5+ cells coexpressing 
TRPV1: 82.3+/-6.8%; CaMKIIα+ cells coexpressing Cdkl5: 83.97+/-3.44%; CaMKIIα+ cells 
coexpressing TRPV1: 84.01+/-5.66%. D. Confocal images showing individual WT or Cdkl5-/y DRG 
neurons (63x, Leica TCS SP5II) after proximity ligation assay (PLA) (red) and DAPI staining (blue). 
The presence and intensity of red dots represent the presence and degree of molecular proximity 
between Cdkl5 and CaMKIIα. E. Graph showing the number of PLA-positive cells in WT 
and Cdkl5/y DRGs. N: 3 animals, Mean with SEM, Student’s t-test, **P<0.005.  
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Figure 4. Cdkl5 is required for outgrowth of human sensory neurons. A,B. Representative 
immunofluorescence of βIII-tubulin, CGRP or Parvalbumin in WT and Cdkl5-/y DRG cultured neurons 
(DIV3) showing reduced neurite outgrowth in CGRP+ but nor Parv+ Cdkl5-/y neurons. C. Graph 
showing reduced neurite outgrowth in CGRP+ neurons from Cdkl5-/y mice (N:5 biological replicates, 
Mean with SD, Student’s t-test, ***P<0.001) that is rescued by CDKL5 overexpression (E; N: 5 
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biological replicates, Mean with SD, One-way ANOVA, Tukey’s post-hoc, **P<0.005). D.  Graph 
showing equal neurite outgrowth in Parv+ neurons from WT and Cdkl5-/y mice. N: 5 biological 
replicates, Mean with SD, Student’s t-test, P>0.05. F. Representative images of CGRP 
immunostaining of iPS derived sensory neurons from three CDKL5 patients carrying unique mutations 
(E55fsX74; G155fsX197; S855X), compared to their isogenic controls (20x images, Nikon TE-2000U 
fluorescence microscope). G. CGRP immunostaining was used to measure total average neurite 
outgrowth (NeuronJ) of nociceptive neurons. N: 5 independent experiments, total neurite 
outgrowth/cell. Mean with SD, Student’s t-test, *P<0.05 **P<0.01.  H. Schematic representation of 
human CDKL5 protein (adapted, (2) with the catalytic domain in blue (ATP-binding site, aa 19-43; 
kinase active site, aa 131-143; TEY motif, aa 169-171) and the C-terminal tail in white (Nuclear 
Localization Signal 1, aa 312-315; Nuclear Localization Signal 2, aa 784-789; Nuclear Export Signal, 
aa 836-845).  
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Figure 5. Cdkl5/CaMKII signaling is required for capsaicin signaling and outgrowth of sensory 
neurons. A. Representative immunofluorescence of DRG cultured neurons (DIV3, from P70 WT and 
Cdkl5-/y mice), immunostained for GFP or HA after neurons had been infected with AAV9 particles 
expressing GFP or HA-CDKL5107 at DIV1 (20x, Nikon TE-2000U fluorescence microscope). DRG 
neurons were also treated with 0.5μM of the CaMKII inhibitor KN93 or its inert structural analog 
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KN92. B. Graphs showing neurite outgrowth of GFP or HA positive cells that was normalized to the 
ctrl WT-GFP. N: 9, biological replicates, Mean with SD, One-way ANOVA, Tukey’s post-hoc, 
****P<0.0001 ***P<0.001 **P<0.005. C. Calcium imaging (Fura-2) from iPS derived nociceptors 
carrying three different CDKL5 mutations (E55fsX74; G155fsX197; S855X), compared with the 
respective isogenic controls. Graphs showing quantification of intracellular calcium in response to 
capsaicin. E55fsX74 and G155fsX197 neurons show reduced calcium influx after capsaicin. N: 5, 
average single cell Fura-2 normalized signal/well (~30 cells per well). Mean with SD, Student’s t-test, 
**P<0.01 *P<0.05. D. Representative transient traces of the calcium amount in DIV3 WT and Cdkl5-
/y neurons (Fura-2 tracks). E-G. Calcium imaging in cultured DRG neurons (Fura-2). DIV3 Cdkl5-/y 
neurons showing reduced calcium influx after capsaicin and rescue to WT amount after overexpression 
of CDKL5 (sspTR-CBh-HA-CDKL5107 vs GFP AAV9 particles, infection at DIV1) (E). The same 
experimental conditions as (D) after pre-treatment with KN93 or KN92 in WT and Cdkl5-/y neurons 
(F), overexpressing CDKL5 or GFP (G). N: 5, average single cell Fura-2 normalized signal /well (~30 
cells per well), Mean with SD, One-way ANOVA, Tukey’s post-hoc, ****P<0.0001 ***P<0.001 
**P<0.005. H. Calcium imaging in DRG-explants from WT and Cdkl5-/y mice. Graphs showing 
quantification of intracellular calcium in response to capsaicin (Fluo-4). N: 5, average single cell Fura-
4 normalized signal /well (~30 cells per well), Mean with SD, Student’s t-test, **P<0.01. 
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Figure 6. Cdkl5 is required for epidermal innervation. A. Immunohistochemical localization of 
Nerve Fibers in the Derm and in the Epiderm of 50 μm murine skin sections (P70), using PGP9.5 as 
specific axonal marker (20x magnification, Zeiss LSM-780 inverted confocal microscope). Sections 
were counterstained for nuclei in Mayer’s Haematoxylin. B. The density of the intra-epidermal nerve 
fibers (IEFN/mm), crossing the dermal-epidermal junction, was analyzed in WT and Cdkl5-/y mice at 
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different developmental stages (P4, P16, P70). N:3, Mean with SD, Two-way ANOVA, Sidak’s post-
hoc, **P<0.005. C. Immunofluorescence of skin biopsies from P70 WT and Cdkl5-/y mice. 
Representative micrographs where collagen IV identifies the epidermal basal lamina and βIII-tubulin 
identifies intra-epidermal nerve fibers (20x magnification, Zeiss LSM-780 inverted confocal 
microscope). D. Individual IENF crossing the dermal–epidermal junction were analyzed. N:4, Mean 
with SD, Student’s t-test, ****P<0.0001. E. The intra-dermal neuronal network (DNet, μm/mm) was 
measured by using Neuron-J software (magnification 20x). N:4, Mean with SD, Student’s t-test, 
P>0.05. F. Western blotting showing the expression of neuronal markers (PGP9.5, βIII-tubulin and 
CGRP) from skin lysates of P16 and P70 WT and Cdkl5-/y mice. G. The immunoblotting bands have 
been quantified by densitometry after normalization with GAPDH used as internal loading control. N: 
3-4 independent experiments, Mean with SD, Two-way ANOVA, Sidak’s post-hoc, ****P<0.0001 
**P<0.005. H. Western blotting showing the expression of PGP9.5, βIII-tubulin and CGRP from 
sciatic nerve lysates in WT and Cdkl5-/y mice. GAPDH was used as loading control. I. Densitometry 
of immunoblotting bands showing no difference between P70-WT and Cdkl5-/y mice was performed 
after normalization to GAPDH. N: 3 independent experiments, Mean with SD, Student’s t-test, P>0.05. 
J. Representative CGRP immunofluorescence of sciatic nerve sections from P70-WT and Cdkl5-/y mice 
(10x, Nikon Eclipse-TE-2000U microscope). K. Graphs showing quantification of the 
immunofluorescence signal display no difference between WT and Cdkl5-/y mice. N: 3 mice per group, 
Mean with SD, Student’s t-test, P>0.05. 
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Figure 7. Cdkl5 deletion impairs capsaicin mediated nociceptive signaling and licking behavior. 
A,B. Bar graphs showing the time spent licking the right paw after the injection of 1µg of capsaicin in 
the posterior right paw vs vehicle injected in the left paw (A: WT vs Cdkl5-/y; B: GFP vs CRE AAV5 
intra-sciatic injected Cdkl5-floxed mice). Time licking the right paw is significantly reduced in Cdkl5-
/y mice and in mice where Cdkl5 was conditionally deleted (cKO) in DRG. A. N: 5 mice each group, 
Mean with SEM, Two-way ANOVA, Sidak’s post-hoc, ****P<0.0001. B. N: 8 mice each group, Mean 
with SEM, Two-way ANOVA, Sidak’s post- hoc, *P<0.05. C. Fisher’s combined probability test 
(false discovery rate, meta-analysis adjusted for multiple testing) of the p-values from the time courses 
in A and B (one statistical test for each time   point).   D.   Representative   confocal   
immunofluorescence   images   for phospho-T286- CaMKIIα in WT and Cdkl5-/y sciatic left and right 
DRG (63x, Leica TCS SP5 II). Tissue was fixed immediately after the capsaicin injection test in the 
right paw (vehicle in the left). E, F. Bar graphs showing the percentage number of positive pCaMKIIα 
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cells (E) and the pCaMKIIα average signal intensity in WT vs Cdkl5-/y left and right DRG-small cells 
after normalization to WT (F). N: 5 mice per group, Mean with SD, One-way ANOVA, Tukey’s post-
hoc, ****P<0.0001 ***P<0.001. G. Schematic illustrating a cross section of the lumbar spinal cord 
emphasizing the left (WT and Mut) and right (WT and Mut) dorsal horns (after injection of vehicle in 
the left paw and capsaicin in the right paw) where nociceptive neurons make a synapse in the lamina 
I-II (L: left, R: right). H. Representative confocal immunofluorescence images for pERK1/2 in WT 
and Cdkl5-/y spinal dorsal horns (10x, Leica TCS SP5 II). Tissue was fixed five minutes after capsaicin 
injection in the posterior right paw vs vehicle injected in the left paw. I. Graph showing lack of 
pERK1/2 activation (signal intensity) in spinal lamina I- II (right side vs left side) in Cdkl5-/y mice vs 
WT. N: 5 mice per group, Mean with SD, Student’s t-test, **P<0.01.




Supplementary Figure 1. A. Representative images of immunostaining for Cdkl5 from WT P4, 
P16 and P70 DRG (20x, Zeiss LSM-780 inverted confocal microscope) showing a clear positive 
signal in adult mice only. B. Graph showing quantification of the immunofluorescence signal 
displaying age-dependent expression (P4, P16, P45, P70). Ratio of the Cdkl5 signal intensity was 
calculated between WT and Cdkl5-/y DRG to subtract the background signal. N: 3-7 mice per 
group, Mean with SD, One-way ANOVA, Tukey’s post-hoc, ***P<0.001 **P<0.005. C. RT-
PCR from WT and Cdkl5-/y adult DRG showing deletion of exon 6 in Cdkl5-/y mice. GAPDH has 
been used as control.  D. Western blotting showing the expression of Cdkl5 in WT that is absent 
in Cdkl5-/y DRG and brain extracts. βIII-tubulin has been used as loading control. E. RT-PCR from 
whole DRG extract or GFP-sorted neurons, showing the expression of CDKL5 mRNA in neurons. 
GAPDH has been used as control, while neurofilament and GFAP have been used as markers of 
neuronal and non-neuronal cells respectively. 






Supplementary Figure 2. A. Representative immunofluorescence images for βIII-tubulin and 
CGRP (10x, Nikon Eclipse-TE-2000U microscope) from isogenic iPS at different stages of 
differentiation into nociceptors (day 0, day 7 and 12). B, C. Graphs showing the percentage of 
CGRP and βIII-tubulin positive cells at the three different maturation stages (DAPI staining was 
used to establish the total number of cells). N: 3 independent experiments (E55fsX74, 





G155fsX197, S855X), Mean with SD, Two-way ANOVA, Sidak’s post-hoc, ****P<0.0001. D. 
Graphs showing that a very high percentage of iPS derived nociceptors (differentiation day 12: 
E55fsX74, G155fsX197, S855X) display CGRP and βIII-tubulin co-expression. Almost the 
totality of differentiated neurons (βIII-tubulin+) are positive for the nociceptor specific marker 
CGRP. No difference was observed between mutant and isogenic control cells or between WT and 
Cdkl5-/y murine DIV3 DRG cultures, where the percentage of βIII-tubulin and CGRP co-
expressing neurons is about 40% of the total number. N: 3 independent experiments, Mean with 
SD, Multiple t-test, Two stage step-up method, P>0.05. E. Graphs showing the percentage of 
capsaicin responding cells compared to the total number of KCl responding DIV-42 iPS derived 
nociceptors (E55fsX74, G155fsX197, S855X) and WT murine DIV3 DRG neurons. Almost the 
totality of the iPS derived neurons respond to capsaicin equally between mutant neurons and their 
isogenic controls. Around 60-70% of DIV3 DRG neurons respond to capsaicin equally between 
WT and Cdkl5-/y cultures. N: 3 independent experiments, Mean with SD, Multiple t-test, Two stage 
step-up method, P>0.05. 
 
Supplementary Figure 3. A. Representative image of AAV5-GFP positive DRG neurons after 
injection of GFP-AAV5 into the sciatic nerve. B. The percentage of infected DRG-neurons in each 
animal (N=5). C. Graph showing time spent on each plate during the thermal place preference test, 
measured at 30 (baseline temperature), 23 and 37°C. WT (black columns, n=10) and mutant mice 
(Cdkl5-KO, white columns, n = 9) prefer the 30°C test plate, compared to the 23 and 37°C plates, 
to the same extent. Mean with SEM, One-way ANOVA, Tukey’s post-hoc; ****P<0.0001, n.s. 
p>0.05. 






Supplementary Figure 4. Graph showing the number of CGRP, IB4 and CaMKIIα 
positive neurons in murine DRG. Three DRG from each mouse (N=3, Mean with S.E.M., t-test) 






Supplementary Figure 5. A. Schematic workflow illustrating the sample preparation and protein 
measurement by mass spectrometry after immunoprecipitation for Cdkl5 from the murine cortex. 
The peptides were labelled LIGHT (DimethLys-0 and DimethNter0) and HEAVY (DimethLys-4 
and DimethNter4; IgG control). B. List of the top 23 proteins enriched in the Cdkl5-IP eluate. The 





statistical significance has been calculated comparing the Log2 ratio values from the Cdkl5 and 
the IgG eluate. N: 6 biological replicates, Parametric Two-tailed test, ****P<0.0001 ***P<0.001 
**P<0.01 *P<0.05. C-F. Classification of the Cdkl5-Co-IP proteins listed in B based upon their 
demonstrated or putative role in epilepsy. 35% of the Cdkl5-Co-IP proteins are “Epilepsy 
Associated Genes” (EAGs) and the 22% are potential EAGs (D, E). Some of the proteins are also 
related with intellectual disabilities, autistic features and other neurodevelopmental disorders (F). 
G. Log2 protein ratio and statistical analysis of the top ranked shows Cdkl5 putative interactors 
related to neurite outgrowth including CaMKIIα. N: 6 biological replicates, Parametric Two-tailed 
test, ****P<0.0001 ***P<0.001 **P<0.01 *P<0.05. H. Western blotting showing co-
immunoprecipitation of CaMKIIα after Cdkl5-pull down from adult murine cortical protein 
extracts. I-J. Representative western blotting showing co-immunoprecipitation of CaMKIIα after 
CDKL5-pull down from HEK-293 Cells overexpressing CaMKIIα together with CDKL5. The co-
immunoprecipitation is impaired when CaMKIIα is co-transfected with the inactive form of 
CDKL5 (Kinase-Dead CDKL5-K42R) (I). The overexpression of the kinases is confirmed by 
Western Blot analysis, while the activity (autophosphorylation) of CDKL5 and CDKL5-K42R 
have been tested in vitro (Kinase Assay followed by SDS-PAGE) (J). 
 
Supplementary Figure 6. Confocal microscopy of immunofluorescence showing co-expression 
of Cdkl5, CaMKIIα and TRPV1 (magnification 20x, SP8 LIGHTNING confocal Leica 
microscope; white arrowheads: co-expression).  






Supplementary Figure 7. A. Western blotting showing the expression of CDKL5 in DRG cultures 
(DIV3) from WT and Cdkl5-/y mice, after AAV9-mediated overexpression of CDKL5. The neurons 
were infected (AAV9-ss-pTR-CBh-HA-CDKL5107) 24 hours after plating. βIII-tubulin was used 
as loading control. B. Bar graphs showing Cdkl5 expression in DRG vs β-III-tubulin housekeeping 
control (N= 7, WT;  5, Cdkl5-/y). 






Supplementary Figure 8. A. Representative immunofluorescence of DRG cultured neurons 
(DIV3, from P70 WT and Cdkl5-/y mice), immunostained for GFP or HA after neurons had been 
infected with AAV expressing EGFP, EGFP-AIP, or HA-CDKL5107 at DIV1 (20x, Nikon TE-
2000U fluorescence microscope). B. Graphs showing neurite outgrowth of infected neurons. 
Neurite outgrowth was reduced following EGFP-AIP and in Cdkl5-/y neurons (b,c,d,f vs a). 
Reduced neurite outgrowth in Cdkl5-/y neurons was rescued after overexpression of CDKL5 in 
EGFP but not in EGFP-AIP expressing neurons (e-g, f-h). N: 3, biological replicates, Mean with 
SD, One-way ANOVA, Tukey’s post-hoc, ****P<0.0001, compared to a. C. Calcium imaging in 
cultured DRG neurons (Fura-2). EGFP expressing Cdkl5-/y neurons and AIP expressing DIV3 WT 
neurons show similar reduced calcium influx after capsaicin. D. The same experimental conditions 





as (C) after infection with AAV8-EGFP or AAV8-EGFP-AIP plus AAV9 carrying GFP or CDKL5 
(sspTR-CBh-HA-CDKL5107, infection at DIV1). The reduced calcium influx, after capsaicin, in 
Cdkl5-/y neurons was rescued after overexpression of CDKL5 in EGFP but not in EGFP-AIP 
expressing neurons. N: 4, average single cell Fura-2 normalized signal/well, Mean with SD, One-
way ANOVA, Tukey’s post-hoc, ***P<0.001 *P<0.05.  
 
Supplementary File 1. Shown is a list of proteins detected by mass spectrometry following 
immunoprecipitation for Cdkl5. Log2 normalized forward and reverse ratios as well as p values 
are provided. 
